Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Preterm birth subtypes, placental pathology findings, and risk of neurodevelopmental disabilities during childhood.

Raghavan R, Helfrich BB, Cerda SR, Ji Y, Burd I, Wang G, Hong X, Fu L, Pearson C, Daniele Fallin M, Zuckerman B, Wang X.

Placenta. 2019 Aug;83:17-25. doi: 10.1016/j.placenta.2019.06.374. Epub 2019 Jun 14.

PMID:
31477202
2.

Corrigendum to 'Maternal vascular malperfusion of the placental bed associated with hypertensive disorders in the Boston Birth Cohort' [Placenta 52 (2017) 106-113].

Helfrich BB, Chilukuri N, He H, Cerda SR, Hong X, Wang G, Pearson C, Burd I, Wang X.

Placenta. 2019 Oct;86:52-53. doi: 10.1016/j.placenta.2019.06.388. Epub 2019 Jul 3. No abstract available.

PMID:
31279486
3.

Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.

Helfrich BA, Gao D, Bunn PA Jr.

Lung Cancer. 2018 Apr;118:148-154. doi: 10.1016/j.lungcan.2018.02.001. Epub 2018 Feb 4.

4.

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.

Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS.

Clin Transl Sci. 2016 Dec;9(6):293-301. doi: 10.1111/cts.12413. Epub 2016 Oct 20.

5.

AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.

Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J.

Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. doi: 10.1158/1078-0432.CCR-16-1179. Epub 2016 Sep 23.

6.

Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.

Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA Jr.

Mol Cancer Ther. 2016 Oct;15(10):2314-2322. Epub 2016 Aug 5.

7.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.

8.

Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.

Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Barón AE, Schulte N, Maxson D, Aisner DL, Franklin WA, Doebele RC, Varella-Garcia M.

Cancer. 2013 Nov 15;119(22):3968-75. doi: 10.1002/cncr.28311. Epub 2013 Sep 10.

9.

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE.

Oncogenesis. 2013 Mar 25;2:e39. doi: 10.1038/oncsis.2013.4.

10.

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC, DeGregori J.

Cancer Res. 2012 Aug 15;72(16):4154-64. doi: 10.1158/0008-5472.CAN-11-2848. Epub 2012 Jun 27.

11.

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE.

PLoS One. 2010 Nov 29;5(11):e14117. doi: 10.1371/journal.pone.0014117.

12.

ZEB1-responsive genes in non-small cell lung cancer.

Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA.

Cancer Lett. 2011 Jan 1;300(1):66-78. doi: 10.1016/j.canlet.2010.09.007. Epub 2010 Oct 25.

13.

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.

Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA Jr, Heasley LE.

Mol Pharmacol. 2009 Jan;75(1):196-207. doi: 10.1124/mol.108.049544. Epub 2008 Oct 10.

14.

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA.

Ann Oncol. 2008 Jun;19(6):1053-9. doi: 10.1093/annonc/mdn006. Epub 2008 Feb 27.

PMID:
18304967
15.

Combining halogen bonds and hydrogen bonds in the modular assembly of heteromeric infinite 1-D chains.

Aakeröy CB, Desper J, Helfrich BA, Metrangolo P, Pilati T, Resnati G, Stevenazzi A.

Chem Commun (Camb). 2007 Nov 7;(41):4236-8.

PMID:
18217591
16.

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr, Raben D.

Mol Cancer Ther. 2007 Jun;6(6):1683-91. Epub 2007 May 31.

17.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

18.

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA Jr.

Mol Cancer Res. 2006 Aug;4(8):521-8.

19.

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA Jr.

Cancer Res. 2006 Jan 15;66(2):944-50.

20.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

21.
22.

Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.

Raben D, Helfrich B, Bunn PA Jr.

Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):27-38. Review.

PMID:
15142632
23.

New lung cancer drugs from bradykinin antagonists.

Stewart JM, Gera L, Chan DC, York EJ, Stewart LT, Simkeviciene V, Helfrich B.

Chest. 2004 May;125(5 Suppl):148S. No abstract available.

PMID:
15136471
24.

Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.

Raben D, Helfrich B, Ciardiello F, Bunn PA.

Lung Cancer. 2003 Aug;41 Suppl 1:S15-22. Review.

PMID:
12867058
25.

Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.

Raben D, Bianco C, Helfrich B, Weng E, Ciardiello F, Harari P.

Expert Rev Anticancer Ther. 2002 Aug;2(4):461-71. Review.

PMID:
12647989
26.

Bradykinin antagonists as new drugs for prostate cancer.

Stewart JM, Chan DC, Simkeviciene V, Bunn PA Jr, Helfrich B, York EJ, Taraseviciene-Stewart L, Bironaite D, Gera L.

Int Immunopharmacol. 2002 Dec;2(13-14):1781-6.

PMID:
12489792
27.

A high-yielding supramolecular reaction.

Aakeröy CB, Beatty AM, Helfrich BA.

J Am Chem Soc. 2002 Dec 4;124(48):14425-32.

PMID:
12452718
28.

Solution and solid-state models of peptide CH...O hydrogen bonds.

Baures PW, Beatty AM, Dhanasekaran M, Helfrich BA, Pérez-Segarra W, Desper J.

J Am Chem Soc. 2002 Sep 25;124(38):11315-23.

PMID:
12236746
29.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA Jr.

Clin Breast Cancer. 2002 May;3 Suppl 1:12-6. Review.

PMID:
12057039
30.

Bradykinin-related compounds as new drugs for cancer and inflammation.

Stewart JM, Gera L, Chan DC, Bunn PA Jr, York EJ, Simkeviciene V, Helfrich B.

Can J Physiol Pharmacol. 2002 Apr;80(4):275-80.

PMID:
12025961
31.
32.

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.

Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA Jr.

Br J Cancer. 2002 May 6;86(9):1449-56.

33.

Syntheses and bioactivities of substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetrones. Unusual reactivities with amines.

Hua DH, Tamura M, Huang X, Stephany HA, Helfrich BA, Perchellet EM, Sperfslage BJ, Perchellet JP, Jiang S, Kyle DE, Chiang PK.

J Org Chem. 2002 May 3;67(9):2907-12.

PMID:
11975545
34.

Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.

Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T, Bunn P Jr.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4608-13.

35.

Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.

Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, Whitehead CM, Piazza G, Pamukcu R, Thompson WJ, Alila H, Nelson P, Bunn PA Jr.

Clin Cancer Res. 2002 Mar;8(3):904-12.

36.

Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.

Bunn PA Jr, Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, Piazza G, Whitehead CM, Pamukcu R, Thompson W, Alila H.

Semin Oncol. 2002 Feb;29(1 Suppl 4):87-94. Review.

PMID:
11894018
38.

Epidermal growth factor receptor family in lung cancer and premalignancy.

Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr.

Semin Oncol. 2002 Feb;29(1 Suppl 4):3-14. Review.

PMID:
11894009
39.

Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.

Bunn PA Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC.

Clin Cancer Res. 2001 Oct;7(10):3239-50.

40.

"Total Synthesis" Supramolecular Style: Design and Hydrogen-Bond-Directed Assembly of Ternary Supermolecules.

Aakeröy CB, Beatty AM, Helfrich BA.

Angew Chem Int Ed Engl. 2001 Sep 3;40(17):3240-3242. doi: 10.1002/1521-3773(20010903)40:17<3240::AID-ANIE3240>3.0.CO;2-X.

PMID:
29712056
41.

Altered HOX and WNT7A expression in human lung cancer.

Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, Rosell R, Gemmill RM, Drabkin HA.

Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12776-81.

42.

Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.

Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC.

Cancer Res. 1999 Dec 15;59(24):6178-84.

43.

Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo.

Bunn PA Jr, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ, Miller YE.

Clin Cancer Res. 1998 Nov;4(11):2849-58.

44.

Reversal of anticancer multidrug resistance by the ardeemins.

Chou TC, Depew KM, Zheng YH, Safer ML, Chan D, Helfrich B, Zatorska D, Zatorski A, Bornmann W, Danishefsky SJ.

Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8369-74.

46.

Carboxypeptidase M. Variable expression in normal human lung and inactivation in lung cancer.

Cohen AJ, Skidgel RA, Gilman LB, Black JK, Bunn PA Jr, Helfrich B, Franklin WA, Miller YE.

Chest. 1997 Jun;111(6 Suppl):149S. No abstract available.

PMID:
9184569
47.

Novel bradykinin antagonist dimers for the treatment of human lung cancers.

Chan D, Gera L, Helfrich B, Helm K, Stewart J, Whalley E, Bunn P.

Immunopharmacology. 1996 Jun;33(1-3):201-4. No abstract available.

PMID:
8856150
48.

Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.

Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE.

Cancer Res. 1996 Feb 15;56(4):831-9.

49.

Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G alpha 16.

Heasley LE, Zamarripa J, Storey B, Helfrich B, Mitchell FM, Bunn PA Jr, Johnson GL.

J Biol Chem. 1996 Jan 5;271(1):349-54.

50.

Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.

McKenzie RS, Simms PE, Helfrich BA, Fisher RI, Ellis TM.

Cancer Res. 1992 Nov 15;52(22):6318-22.

Supplemental Content

Loading ...
Support Center